Endpoint surrogacy in oncology Phase 3 randomised controlled trials

Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianrong, Pilar, Meagan R., Wang, Xiaofei, Liu, Jingxia, Pang, Herbert, Brownson, Ross C., Colditz, Graham A., Liang, Wenhua, He, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403397/
https://www.ncbi.nlm.nih.gov/pubmed/32451466
http://dx.doi.org/10.1038/s41416-020-0896-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403397/
https://www.ncbi.nlm.nih.gov/pubmed/32451466
http://dx.doi.org/10.1038/s41416-020-0896-5

Ejemplares similares